These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
chrxiv-Chernyshev.pdf (1.2 MB)
Pharmaceutical Targeting the Envelope Protein of SARS-CoV-2: the Screening for Inhibitors in Approved Drugs
Preprints are manuscripts made publicly available before they have been submitted for formal peer review and publication. They might contain new research findings or data. Preprints can be a draft or final version of an author's research but must not have been accepted for publication at the time of submission.
overview of the biological role of coronavirus viroporin (envelope
protein) is given, together with the effect of its known inhibitors on
the life cycle of coronavirus. A docking study is conducted using a set
of known drugs approved worldwide (ca. 6000 compounds) on a structure of
the SARS-CoV-2 viroporin modelled from the published NMR-resolved
structures. The screening has identified 36 promising drugs currently on
the market, which could be proposed for pre-clinical trials.